Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607, HKG: 2607)’s subsidiary MediTrust Health, which specializes in insurance, financing, and direct-to-patient pharmacy services, has entered into a partnership with Japan’s Eisai to jointly address the prevention, control, and security of Alzheimer’s disease (AD).
The collaboration aims to develop a comprehensive health management system tailored for middle-aged and elderly individuals, encompassing prevention, early screening, treatment, and long-term disease management. Additionally, MediTrust Health plans to collaborate with various insurance companies to offer diverse insurance and payment solutions for this demographic.
Eisai’s Alzheimer’s therapy, Leqembi (lecanemab), which targets amyloid-beta (Aβ), received marketing approval in China in January this year for treating mild cognitive impairment (MCI) and mild dementia associated with Alzheimer’s disease.- Flcube.com
